Recent Patents on Anti-Cancer Drug Discovery 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Intracholecystic Papillary-tubular Neoplasm (ICPN) of the Gallbladder: A Case Report Focusing on an Unexpected Pathological Finding
CONCLUSION: A comprehensive understanding of neoplastic polyps of the gallbladder is still limited. Pathological examination of these lesions is crucial for identifying key features that can influence patient outcomes and survival.PMID:37885107 | DOI:10.2174/0115748928256837231012151452 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 27, 2023 Category: Cancer & Oncology Authors: Antonio Pesce Valentina Sani Alba Gaban Nicol ò Fabbri Massimo Tilli Roberta Gaf à Carlo Vittorio Feo Source Type: research
Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma
CONCLUSION: Elevated HNRNPA2B1 is a risk factor in LUAD and portends a poor prognosis.PMID:37877146 | DOI:10.2174/0115748928258696230925064550 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 25, 2023 Category: Cancer & Oncology Authors: Wei Wang Shengwei Li Source Type: research
Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening
CONCLUSION: CSF3R participates in the occurrence and development of OS bone destruction by regulating the inflammatory response of osteoblasts and osteoclasts and can affect the survival prognosis of OS patients.PMID:37877147 | DOI:10.2174/0115748928259095231010055507 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 25, 2023 Category: Cancer & Oncology Authors: Qian Li Jinlu Shan Wei Duan Yu Chen Source Type: research
Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma
CONCLUSION: Elevated HNRNPA2B1 is a risk factor in LUAD and portends a poor prognosis.PMID:37877146 | DOI:10.2174/0115748928258696230925064550 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 25, 2023 Category: Cancer & Oncology Authors: Wei Wang Shengwei Li Source Type: research
Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening
CONCLUSION: CSF3R participates in the occurrence and development of OS bone destruction by regulating the inflammatory response of osteoblasts and osteoclasts and can affect the survival prognosis of OS patients.PMID:37877147 | DOI:10.2174/0115748928259095231010055507 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 25, 2023 Category: Cancer & Oncology Authors: Qian Li Jinlu Shan Wei Duan Yu Chen Source Type: research
Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma
CONCLUSION: Elevated HNRNPA2B1 is a risk factor in LUAD and portends a poor prognosis.PMID:37877146 | DOI:10.2174/0115748928258696230925064550 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 25, 2023 Category: Cancer & Oncology Authors: Wei Wang Shengwei Li Source Type: research
